# Desidustat in the Treatment of Anemia in CKD

Study · id `cardio:ct-nct04012957` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04012957](<https://clinicaltrials.gov/study/NCT04012957>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04012957

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.

## Technical summary

Registry record NCT04012957. Randomized; no masking; primary purpose treatment. Start 2019-07-20 (actual); primary completion 2021-08-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 588 participants (enrolled count; ClinicalTrials.gov record NCT04012957, source copy `cardio:ctgov-nct04012957-2021-11-24`, retrieved 2026-10-26)
- Started: 2019-07-20 (actual) (ClinicalTrials.gov record NCT04012957, source copy `cardio:ctgov-nct04012957-2021-11-24`, retrieved 2026-10-26)
- Primary completion: 2021-08-25 (actual) (ClinicalTrials.gov record NCT04012957, source copy `cardio:ctgov-nct04012957-2021-11-24`, retrieved 2026-10-26)
- Completion: 2021-08-25 (actual) (ClinicalTrials.gov record NCT04012957, source copy `cardio:ctgov-nct04012957-2021-11-24`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT04012957, source copy `cardio:ctgov-nct04012957-2021-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04012957-2021-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Desidustat in the Treatment of Anemia in CKD
- Acronym: DREAM-ND
- Condition: Chronic Kidney Disease Stage 3
- Condition: Anemia
- Condition: Chronic Kidney Disease Stage 4
- Condition: Chronic Kidney Disease Stage 5
- Intervention (Drug): Desidustat Oral Tablet
- Intervention (Drug): Darbepoetin Alfa
- Lead sponsor: Zydus Lifesciences Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Zydus Lifesciences Limited (`cardio:org-zydus-lifesciences-limited`)

## Provenance

Content hash: 81f9df36eff308a9dadf12e40963c6be0e8935f016231e4b8fec4efae027e0f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
